1. Home
  2. CTNM vs EAF Comparison

CTNM vs EAF Comparison

Compare CTNM & EAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • EAF
  • Stock Information
  • Founded
  • CTNM 2009
  • EAF 1886
  • Country
  • CTNM United States
  • EAF United States
  • Employees
  • CTNM N/A
  • EAF N/A
  • Industry
  • CTNM
  • EAF Industrial Machinery/Components
  • Sector
  • CTNM
  • EAF Energy
  • Exchange
  • CTNM Nasdaq
  • EAF Nasdaq
  • Market Cap
  • CTNM 377.6M
  • EAF 437.2M
  • IPO Year
  • CTNM 2024
  • EAF 1995
  • Fundamental
  • Price
  • CTNM $11.28
  • EAF $1.76
  • Analyst Decision
  • CTNM Strong Buy
  • EAF Hold
  • Analyst Count
  • CTNM 4
  • EAF 6
  • Target Price
  • CTNM $29.25
  • EAF $1.80
  • AVG Volume (30 Days)
  • CTNM 135.4K
  • EAF 1.8M
  • Earning Date
  • CTNM 02-16-2025
  • EAF 02-07-2025
  • Dividend Yield
  • CTNM N/A
  • EAF N/A
  • EPS Growth
  • CTNM N/A
  • EAF N/A
  • EPS
  • CTNM N/A
  • EAF N/A
  • Revenue
  • CTNM N/A
  • EAF $541,710,000.00
  • Revenue This Year
  • CTNM N/A
  • EAF N/A
  • Revenue Next Year
  • CTNM N/A
  • EAF $5.07
  • P/E Ratio
  • CTNM N/A
  • EAF N/A
  • Revenue Growth
  • CTNM N/A
  • EAF N/A
  • 52 Week Low
  • CTNM $11.38
  • EAF $0.52
  • 52 Week High
  • CTNM $22.00
  • EAF $2.53
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • EAF 50.71
  • Support Level
  • CTNM N/A
  • EAF $1.50
  • Resistance Level
  • CTNM N/A
  • EAF $1.75
  • Average True Range (ATR)
  • CTNM 0.00
  • EAF 0.13
  • MACD
  • CTNM 0.00
  • EAF 0.02
  • Stochastic Oscillator
  • CTNM 0.00
  • EAF 65.00

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About EAF GrafTech International Ltd.

GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two major product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.

Share on Social Networks: